Table 3 Analysis of individual SNP effects on breast cancer. Estimated odds-ratios (OR) and 95% confidence intervals (CI) associated with each of the 19 polymorphisms selected under co-dominant age-adjusted main effect models (the significant associations are in bold).
SNP | Genotype | Cases n (%) | Controls n (%) | OR* | 95% CI |
|---|---|---|---|---|---|
COMT | AA | 94 (23.6) | 96 (25.8) | 1.0. | - |
Met108/158Val | AG | 202 (50.8) | 196 (52.7) | 1.3 | (0.9–1.9) |
|  | GG | 102 (25.6) | 80 (21.5) | 1.3 | (0.9–2.0) |
CCND1 | GG | 104 (26.1) | 114 (30.6) | 1.0. | - |
Pro241Pro | AG | 203 (51.0) | 178 (47.8) | 1.3 | (0.9–1.9) |
|  | AA | 91 (22.9) | 80 (21.5) | 1.3 | (0.9–1.8) |
IL13 | GG | 240 (60.3) | 252 (67.8) | 1.0. | - |
Arg130Gln | AG | 144 (36.2) | 105 (28.2) | 0.8 | (0.4–1.8) |
|  | AA | 14 (3.5) | 15 (4.0) | 1.2 | (0.9–1.6) |
IL1A | GG | 204 (51.3) | 179 (48.1) | 1.0. | - |
Ala114Ser | GT | 155 (38.9) | 164 (44.1) | 1.0 | (0.7–1.3) |
|  | TT | 39 (9.8) | 29 (7.8) | 1.7 | (1.0–2.8) |
G-CSF | AA | 146 (36.7) | 138 (37.1) | 1.0. | - |
Leu185Leu | AG | 193 (48.5) | 182 (48.9) | 1.0 | (0.7–1.3) |
|  | GG | 59 (14.8) | 52 (14.0) | 1.1 | (0.7–1.8) |
ESR1 | TT | 107 (26.9) | 97 (26.1) | 1.0. | - |
Ser10Ser | CT | 200 (50.3) | 187 (50.3) | 1.1 | (0.7–1.6) |
|  | CC | 91 (22.9) | 88 (23.7) | 1.1 | (0.7–1.4) |
TNF-A | GG | 274 (68.8) | 237 (63.7) | 1.0. | - |
G(-308)A | AG | 113 (28.4) | 120 (32.2) | 0.9 | (0.4–2.1) |
|  | AA | 11 (2.8) | 15 (4.0) | 0.9 | (0.7–1.2) |
CYP17 | TT | 170 (42.7) | 172 (46.2) | 1.0. | - |
C(518)T | CC | 60 (15.1) | 49 (13.2) | 1.5 | (1.0–2.4) |
|  | CT | 168 (42.2) | 151 (40.6) | 1.3 | (0.9–1.7) |
BARD1 | CC | 174 (43.7) | 142 (38.2) | 1.0. | - |
Pro24Ser | CT | 188 (47.2) | 184 (49.5) | 0.8 | (0.6–1.1) |
|  | TT | 36 (9.0) | 46 (12.4) | 0.8 | (0.5–1.2) |
XPD | AA | 146 (36.7) | 165 (44.3) | 1.0. | - |
Lys751Gln | AC | 194 (48.7) | 167 (44.9) | 1.3 | (0.9–1.7) |
|  | CC | 58 (14.6) | 40 (10.8) | 1.6 | (1.0–2.6) |
IL10 | AA | 90 (22.6) | 107 (28.7) | 1.0. | - |
G(-1082)A | AG | 205 (51.5) | 194 (52.2) | 1.1 | (0.7–1.5) |
|  | GG | 103 (25.9) | 71 (19.1) | 1.1 | (0.7–1.6) |
ESR1 | CC | 243 (61.1) | 213 (57.3) | 1.0. | - |
Pro325Pro | CG | 126 (31.7) | 138 (37.1) | 1.0 | (0.7–1.3) |
|  | GG | 29 (7.3) | 21 (5.6) | 1.0 | (0.5–1.8) |
MTHFR | CC | 162 (40.7) | 160 (43.0) | 1.0. | - |
Ala222Val | CT | 170 (42.7) | 161 (43.3) | 1.1 | (0.8–1.5) |
|  | TT | 66 (16.6) | 51 (13.7) | 1.3 | (0.8–2.0) |
GSTP1 | AA | 208 (52.3) | 175 (47.0) | 1.0. | - |
Ile105Val | AG | 149 (37.4) | 161 (43.3) | 1.1 | (0.8–1.5) |
|  | GG | 41 (10.3) | 36 (9.7) | 1.3 | (0.8–2.0) |
GADD45 | TT | 189 (47.5) | 177 (47.6) | 1.0. | - |
C(IVS3+168)T | CC | 32 (8.0) | 43 (11.6) | 0.8 | (0.5–1.3) |
|  | CT | 177 (44.5) | 152 (40.9) | 0.9 | (0.7–1.2) |
P27 | TT | 256 (64.3) | 235 (63.2) | 1.0. | - |
Val109Gly | GG | 17 (4.3) | 15 (4.0) | 1.0 | (0.5–2.0) |
|  | GT | 125 (31.4) | 122 (32.8) | 1.0 | (0.7–1.3) |
MMP1 | Del/del | 110 (27.6) | 104 (28.0) | 1.0. | - |
1G(-1607)2G | Ins/ins | 92 (23.1) | 94 (22.6) | 0.8 | (0.6–1.3) |
|  | Ins/del | 196 (49.2) | 184 (49.5) | 1.0 | (0.7–1.4) |
PTEN | Del/del | 171 (43.0) | 196 (52.7) | 1.0. | - |
(IVS4+109) ins/delACTAA | Ins/ins | 47 (11.8) | 38 (10.2) | 1.3 | (0.8–2.1) |
|  | Ins/del | 180 (45.2) | 138 (37.1) | 1.2 | (0.9–1.7) |
GSTM3 | Ins/ins | 271 (68.1) | 272 (73.1) | 1.0. | - |
4595 (3bp ins/del) | Del/del | 7 (1.8) | 9 (2.4) | 0.9 | (0.4–2.1) |
|  | Ins/del | 120 (30.1) | 91 (24.5) | 0.9 | (0.7–1.3) |